Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Clinicians need to consider treatments for episodic migraine that may be contraindicated if a patient also has cardiovascular disease.
Future predictive models may need to include other migraine risk factors to enhance predictive accuracy.
Treatment with the monoclonal antibody erenumab reduced the number of monthly migraine days experienced in patients with episodic migraine.
Over 50% of participants reported having an inadequate response to treatment.
Phase 2 results show anti-CGRP receptor monoclonal antibody effective for the prevention of episodic migraine.
Treatment that provides rapid, consistent migraine relief may help mediate factors that promote inadequate treatment response.
Adults taking the drug combo experienced a decreased amount of migraine days compared to placebo.
A simple lipid panel may distinguish those with episodic migraine.
Neurology Advisor Articles
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Initial Treatment With Ethosuximide Improves Behavioral Outcomes in Childhood Absence Epilepsy
- Bevacizumab Wins Full FDA Approval for Glioblastoma Treatment
- Men With Parkinson Disease More Likely to Have Caregiver
- Diet Linked to Multiple Sclerosis Disability, Disease Severity